INOVIO Class Action Alert: Law Firm Bragar Eagel & Squire, P.C. Announces…

Investors who have incurred losses in Inovio Pharmaceuticals, Inc. are encouraged to address their concerns and explore their options with Bragar Eagel & Squire, P.C. Litigation Partner, Brandon Walker. The law firm has initiated a class action lawsuit against Inovio on behalf of investors who purchased or acquired Inovio securities between October 10, 2023, and December 26, 2025.

According to the lawsuit filed in the United States District Court for the Eastern District of Pennsylvania, it is alleged that throughout the Class Period, Inovio made false and misleading statements or failed to disclose certain crucial information. The lawsuit asserts that Inovio’s manufacturing processes for the CELLECTRA device were inadequate. Consequently, Inovio was unlikely to submit the INO-3107 Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) by the second half of 2024. Additionally, the lawsuit claims that Inovio lacked sufficient data to support the INO-3107 BLA’s eligibility for accelerated approval or priority review, overstating the regulatory and commercial prospects of INO-3107. As a result, the lawsuit contends that defendants’ public statements were materially false and misleading.

The market received a shock on December 29, 2025, when the FDA announced it had accepted Inovio’s BLA for INO-3107, a treatment for recurrent respiratory papillomatosis, on a standard review timeline. Inovio had submitted its BLA for accelerated approval, but the FDA declared that the Company had not provided enough information to justify eligibility for accelerated approval. In addition, Inovio disclosed it did not intend to pursue approval under the standard review timeline and would request a meeting with the FDA to explore options for accelerated approval. Following this news, Inovio’s stock experienced a significant decline, dropping $0.56 per share, or 24.45%, to close at $1.73 per share.

Investors who purchased or acquired Inovio shares and suffered losses, as well as long-term stockholders with information or queries about the claims made, are urged to contact Brandon Walker or Melissa Fortunato for further assistance. Interested parties can reach out via email or phone with no cost or obligation attached to the consultations.

Bragar Eagel & Squire, P.C. is a distinguished law firm with a presence in New York, South Carolina, and California. The firm is dedicated to representing individuals in legal matters and advocating for their rights and best interests. If you are an investor who has been impacted by the developments surrounding Inovio, do not hesitate to reach out to Bragar Eagel & Squire, P.C. to discuss your situation and explore potential courses of action.